For sales

📢 Highlights from April 21 to 25 in the world of pharma and healthcare! 🗞️👀

VYUHPHARMA Akesobio Akeso's ivonescimab combined with chemotherapy, shows statistically significant and positive Phase 3 results in the first-line treatment of sq-NSCLC compared to tislelizumab with chemotherapy (Clinical data, Phase 3) REPERTOIRE R Repertoire Immune Medicines has partnered with Genentech to develop T cell-targeted immune therapies for autoimmune diseases using the DECODE platform DAAN DAAN Biotherapeutics has signed an exclusive licensing agreement with GC Cell for a tumor antigen-specific antibody sequence in CAR-T and CAR-NK therapy development (collaboration) (Agreement) All logos and trademarks remain the intellectual properties of their respective owners
Download

Connect with us

Please fill in the information below, and we'll get back to you.